The permission to file an IND allows the company to design a proof-of-concept study in COVID-19 patients evaluating clinical doses of FSD-20. The primary endpoint of the study is to determine if adding FSD-201 to the standard of care will significantly improve the time to symptom relief.
Key secondary objectives include additional benefit in terms of safety, and length of time in the improvement of oxygen saturation, among others.
The company said the therapeutic effects of ultramicronized palmitoylethanolamide are supported by more than 600 scientific papers.
Price: 6.8000, Change: +3.70, Percent Change: +119.35
|Manufacturing in New York Rises More Than Expected i...|
|NTSB Probe Blames Pilot Error in Fatal February 2019...|
|-- (WINA) WINMARK CORP Posts Q2 EPS $1.33|
|--(WINA) WINMARK CORP Posts Q2 Revenue $12.39M|
|Waste Management to Redeem $3 Billion of Notes as Ac...|